BiotechTube

Ruxolitinib Cream 1.5%

Phase 1Completed
0 watching 0 views this week💤 Quiet
30
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Prurigo Nodularis

Conditions

Prurigo Nodularis

Trial Timeline

Feb 27, 2024 → Jul 17, 2025

NCT ID
NCT06213831

About Ruxolitinib Cream 1.5%

Ruxolitinib Cream 1.5% is a phase 1 stage product being developed by Incyte for Prurigo Nodularis. The current trial status is completed. This product is registered under clinical trial identifier NCT06213831. Target conditions include Prurigo Nodularis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
7
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06213831Phase 1Completed

Competing Products

20 competing products in Prurigo Nodularis

See all competitors
ProductCompanyStageHype Score
Vixarelimab + PlaceboKiniksa PharmaceuticalsPhase 2
47
UpadacitinibAbbVieApproved
85
Pimecrolimus + Hydrocortisone + PimecrolimusNovartisPhase 2
52
Rocatinlimab + PlaceboAmgenPhase 3
76
AbrocitinibPfizerPhase 2
51
Dupilumab SAR231893 (REGN668)SanofiPre-clinical
22
DupilumabSanofiPhase 3
76
DupilumabSanofiPre-clinical
22
DupilumabSanofiPre-clinical
22
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
INCB054707 + PlaceboIncytePhase 2
49
Povorcitinib + PlaceboIncytePhase 3
74
Povorcitinib + PlaceboIncytePhase 3
74
Ruxolitinib Cream + Vehicle CreamIncytePhase 3
74
CDX-0159 + Normal salineCelldex TherapeuticsPhase 1
28
barzolvolimabCelldex TherapeuticsPhase 2
47
nalbuphine HCl ER tablets 90 mg BID + nalbuphine HCl ER tablets 180 mg BID + Placebo tablets BIDTrevi TherapeuticsPhase 2/3
60
nalbuphine HCl ERTrevi TherapeuticsPhase 2/3
60
Nalbuphine ER Tablets + Placebo TabletsTrevi TherapeuticsPhase 2/3
60
serlopitant + PlaceboVyne TherapeuticsPhase 2
44

Other Products from Incyte

ruxolitinib creamApproved
82
Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3
74
Povorcitinib + PlaceboPhase 3
74
Ruxolitinib Cream + Vehicle CreamPhase 3
74
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3
74